

New Drug, Generic, and Biosimilar Pipeline Report

Q3 2024

What follows is a summary of significant predicted forthcoming drug launches of newly approved brand drugs, generic drug, and biosimilars.

New Drug Pipeline

GENERIC NAME	BRAND NAME (Manufacturer if drug name unavailable)	ROUTE OF ADMINISTRATION	STATUS	ESTIMATED COST	THERAPEUTIC AREA	SPECIALTY OR TRADITIONAL
Mavoxifafor	Xolremdi	Oral	Approved Apr 2024	\$100,000-\$200,000 annually	Autoimmune	Specialty
Pivmecillinam	Pivya	Oral	Approved Apr 2024	\$200-\$500 per course	Anti-Infectives: Antibiotics	Traditional
Tovorafenib	Ojemda	Oral	Approved Apr 2024	\$250,000 annually	Cancer: Brain	Specialty
Danicopan	Voydeya	Oral	Launched Apr 2024	\$50,000 annually	Hematologic: Paroxysmal nocturnal hemoglobinuria	Specialty
Rivoceranib	(Jiangsu Hengrui Medicine LSK BioPharma)	Oral	CRL May 2024	TBD	Cancer: Gastrointestinal	Specialty
Elafibranor	Iqirvo	Oral	Approved Jun 2024	139,430	Endocrine: Primary Biliary Cholangitis	Specialty
Sofpironium	Sofdra	Topical	Approved Jun 2024	\$5,000-\$10,000 annually	Dermatology: Hyperhidrosis	Traditional
Crovalimab	PiaSky	Intravenous/ Subcutaneous	Approved Jun 2024	\$450,000	Hematological: Paroxysmal Nocturnal Hemoglobinuria	Specialty
Ensifentrine	(Ligand Pharma)	Inhaled	Jun 2024	\$18,000 annually	Respiratory: Asthma/COPD	Traditional
Follitropin Delta	Rekovele	Subcutaneous*	1H2024	TBD	Endocrine: Infertility	Specialty
Deuruxolitinib	(Concert/Sun)	Oral	Jul 2024	TBD	Dermatology: Alopecia Areata	Specialty
Galantamine Benzoate	(Alpha Cognition)	Oral	Jul 2024	TBD	Central Nervous System: Alzheimer's/Dementia	Traditional
Naloxone	Orexo	Nasal*	Jul 2024	TBD	Addiction/Substance Abuse	Traditional
Palopegteriparatide	TransCon PTH	Subcutaneous	May 2024 Aug 2024	\$100,000-\$300,000 annually	Endocrine: Hypoparathyroidism	Specialty
Midomafetamine (MDMA)	(MAPS PBC; Lykos Therapeutics)	Oral	2H2024 Aug 2024	\$5,000-\$10,000 per course	Central Nervous System: Mood Disorders	Specialty
Seladelpar	(CymaBay Therapeutics)	Oral	2H2024 Aug 2024	\$110,000 annually	Gastrointestinal: Primary biliary cholangitis	Specialty

Key

Launched MM YYYY Month and year drug was launched
Approved MM YYYY Month and year drug was approved
Date-Date Updated release date

Withdrawn Drug has been withdrawn from FDA approval
CRL Complete Response Letter - Incomplete FDA Application

New Drug Pipeline

GENERIC NAME	BRAND NAME (Manufacturer if drug name unavailable)	ROUTE OF ADMINISTRATION	STATUS	ESTIMATED COST	THERAPEUTIC AREA	SPECIALTY OR TRADITIONAL
Vorasidenib	(Servier Laboratories)	Oral	Aug 2024	TBD	Cancer: Glioma	Specialty
Arimoclomol	Miplyffa	Oral	Jun 2024 Sept 2024	\$500,000-\$1,000,000	Endocrine: Niemann-Pick disease Type C	Specialty
Ocrelizumab	Ocrevus	Subcutaneous	Sept 2024	\$78,000	Central Nervous System: Multiple Sclerosis	Specialty
Revumenib	(Syndax)	Oral	2H2024 Sept 2024	TBD	Cancer: Leukemia	Specialty
Tradipitant	(Vanda Pharmaceuticals)	Oral	Sept 2024	\$10,000 per course	Gastroenterology: Nausea	Specialty
Xanomeline; Trosipium Chloride	KarXT	Oral	Sept 2024	\$20,000-\$30,000 annually	Central Nervous System: Schizophrenia	Traditional
Lebrikizumab	(Eli Lilly)	Subcutaneous	2H2024 Oct 2024	\$50,000	Dermatology: Atopic Dermatitis	Specialty
Acoramidis	(BridgeBio/Eidos Therapeutics)	Oral	4Q2024 Nov 2024	\$200,000 - \$300,000 annually	Endocrine: Metabolic	Specialty
Govorestat	(Applied Therapeutics)	Oral	2H2024 Nov 2024	TBD	Endocrine: Metabolic	Specialty
Nemolizumab	Mitchga	Subcutaneous	Aug024 Dec 2024	TBD	Dermatology	Specialty
Rilpivirine	Edurant	Oral	2Q2024	\$17,700 annually	Anti-Infectives: HIV	Traditional
Insulin icodec	(Novo Nordisk)	Subcutaneous	2Q2024 3Q2024	\$5,000 annually	Endocrine:Diabetes	Traditional
Glepaglutide	(Zeland Pharma)	Subcutaneous	Dec 2024	\$540,000 annually	Gastrointestinal: Short Bowel Syndrome	Specialty
Lazertinib	(YuHan)	Oral	4Q2024	TBD	Cancer: Non- Small Cell Lung Cancer	Specialty
Vicagrel	(Jiangsu Vcare Pharmatech)	Oral	4Q2024	\$5,000-\$10,000 annually	Cardiovascular: Acute Coronary Syndrome	Specialty

Generic and Biosimilar Pipeline

DRUG NAME	BRAND NAME	ROUTE OF ADMINISTRATION	STATUS	ESTIMATED 2023 US SALES (MILLIONS)	THERAPEUTIC AREA	BIOSIMILAR OR TRADITIONAL
Risperidone	Risvan	Intramuscular	Approved Apr 2024	\$15,000-\$35,000/year	Central Nervous System: Antipsychotic	Traditional
Hercessi (Trastuzumab)	Herceptin	Intravenous	2H2024 Apr 2024	\$559	Cancer: Breast	Biosimilar
Xlucane (Ranibizumab)	Lucentis	Intravitreal*	CRL Apr 2024	\$1,242	Ophthalmic: Macular Degeneration	Biosimilar
Edaravone	Radicava	Intravenous	Approved May 2024	\$330	Central Nervous System: ALS	Biosimilar

Key

Launched MM YYYY Month and year drug was launched
 Approved MM YYYY Month and year drug was approved
 Date-Date Updated release date

Withdrawn
 CRL

Drug has been withdrawn from FDA approval
 Complete Response Letter - Incomplete FDA Application

Generic and Biosimilar Pipeline

DRUG NAME	BRAND NAME	ROUTE OF ADMINISTRATION	STATUS	ESTIMATED 2023 US SALES (MILLIONS)	THERAPEUTIC AREA	BIOSIMILAR OR TRADITIONAL
Aflibercept	Eylea	Intravitreal	Jun 2024	\$6,795	Ophthalmic: Macular Degeneration	Biosimilar
Liraglutide	Victoza	Subcutaneous	Approved Jun 2024	\$3,678	Endocrine: Diabetes	Traditional
Nilotinib	Tasigna	Oral	Jan 2024 1H2024	\$1,242	Cancer: Leukemia	Biosimilar
Dasatinib	Sprycel	Oral	Sept 2024	\$2,528	Cancer	Biosimilar
Oxcarbazepine	Oxtellar XR	Oral	Sept 2024	\$230	Central Nervous System: Epilepsy	Traditional
Denosumab	Prolia	Subcutaneous	Nov 2024	\$3,753	Cancer	Biosimilar
Phentermine/Topiramate	Qsymia	Oral	Dec 2024	\$51	Endocrine: Obesity	Traditional
Raltegravir	Isentress	Oral	2024	\$355	Anti-Infectives: HIV	Traditional
Teduglutide	Gattex	Subcutaneous	2024	\$500	Gastrointestinal	Biosimilar
Toclizumab (Tyenne)	Actemra	Intravenous*	2024-2025 Jan 2025	\$1,048	Anti-Inflammatory	Biosimilar
Ustekinumab	Stelara	Subcutaneous	Jan 2025	\$20,616	Anti-Inflammatory	Biosimilar

Nothing herein is or shall be construed as a promise or representation regarding past or future events and Serve You Rx expressly disclaims any and all liability relating to the use or reliance on the information contained in this publication. The information contained in this publication is intended for educational purposes only and should not be considered clinical, financial, or legal advice. By receipt of this publication, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, distributed to, or disclosed to others at any time without the prior written consent of Serve You Rx.

*New Formulation of an Existing Product

Source: IPD Analytics, 2024

ServeYouRx.com | 800-759-3203

Key

Launched MM YYYY Month and year drug was launched
 Approved MM YYYY Month and year drug was approved
 Date-Date Updated release date

Withdrawn Drug has been withdrawn from FDA approval
 CRL Complete Response Letter - Incomplete FDA Application